Millie Das, MD
Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and is an active member of the VA national Lung Cancer Working Group and Lung Cancer Precision Oncology Program. She is currently serving on the board of directors for the Association of Northern California Oncologists (ANCO), where she displays her passion for patient advocacy and also for clinician education by helping to organize Bay Area focused continuing medical education programs. She is the VA site director for the Stanford fellowship program and leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Sanofi/GenzymeTopic:lung cancer advisory boardDate added:07/31/2023Date updated:03/05/2024Relationship end date:05/24/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:RegeneronTopic:lung cancer advisory boardDate added:07/31/2023Date updated:03/05/2024Relationship end date:09/30/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:EurofinsTopic:consultingDate added:07/31/2023Date updated:03/05/2024Relationship end date:04/13/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JanssenTopic:lung cancer advisory boardDate added:07/31/2023Date updated:03/05/2024Relationship end date:04/20/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Astra ZenecaTopic:lung cancer educational programDate added:07/31/2023Date updated:03/05/2024Relationship end date:09/23/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:MerckTopic:KEYNOTE-867Date added:07/31/2023Date updated:03/05/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:GenentechTopic:IMForteDate added:07/31/2023Date updated:03/05/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NovartisTopic:CANOPY-ADate added:07/31/2023Date updated:03/05/2024Relationship end date:04/24/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:CellSightTopic:Ara-G clinical trialDate added:07/31/2023Date updated:03/05/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GileadTopic:lung cancer advisory boardDate added:08/01/2023Date updated:03/05/2024Relationship end date:07/26/2023